DIABETIK RETINOPATIYADA ANTI‑VEGF TERAPIYASINING SAMARADORLIGI: KENGAYTIRILGAN VA PARAFRAZ QILINGAN ADABIYOTLAR TAHLILI
Keywords:
diabetic retinopathy, anti-VEGF therapy, diabetic macular edema, vascular endothelial growth factor, intravitreal injections, visual acuity, retinal thickness, neovascularization.Abstract
Diabetik retinopatiya qandli diabetning eng muhim mikroangiopatik asoratlaridan biri bo‘lib, butun dunyo bo‘yicha mehnatga layoqatli aholida ko‘rishning pasayishiga olib keluvchi asosiy sabablar qatoriga kiradi. Epidemiologik tadqiqotlar diabet bilan yashayotgan bemorlarning qariyb uchdan bir qismida retinopatik o‘zgarishlar rivojlanishini ko‘rsatadi [1]. So‘nggi yillarda tomir endotelial o‘sish faktori (VEGF) kasallik patogenezida markaziy rol o‘ynashi aniqlanib, unga qarshi yo‘naltirilgan biologik preparatlar klinik amaliyotga keng joriy etildi. Mazkur maqolada anti‑VEGF terapiyasining patofiziologik asoslari, klinik samaradorligi, xavfsizlik ko‘rsatkichlari hamda uzoq muddatli natijalari ilmiy adabiyotlar asosida tahlil qilinadi.
References
1. Yau J. W. Y. et al. Global prevalence and major risk factors of diabetic retinopathy //Diabetes care. – 2012. – Т. 35. – №. 3. – С. 556-564.
2. Federation I. D. IDF Diabetes Atlas 2021 //International Diabetes Federation. – 2021.
3. Klein R. The Wisconsin epidemiologic study of diabetic retinopathy //Archives of Ophthalmology. – 1989. – Т. 107. – №. 2. – С. 244.
4. Early Treatment Diabetic Retinopathy Study Research Group et al. Early treatment diabetic retinopathy study report number 1; Photocoagulation for diabetic macular edema //Arch Ophthalmol. – 1985. – Т. 103. – С. 1796-1806.
5. Antonetti D. A., Klein R., Gardner T. W. Mechanisms of disease diabetic retinopathy //New England Journal of Medicine. – 2012. – Т. 366. – №. 13. – С. 1227-1239.
6. Aiello L. P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders //New England Journal of Medicine. – 1994. – Т. 331. – №. 22. – С. 1480-1487.
7. Wells JA et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193-1203.
8. Nguyen Q. D. et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE //Ophthalmology. – 2012. – Т. 119. – №. 4. – С. 789-801.
9. Virgili G et al. Anti-VEGF for diabetic macular oedema. Cochrane Database Syst Rev. 2018.
10. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating intravitreal ranibizumab. Ophthalmology. 2010.
11. Avery RL et al. Systemic safety of prolonged monthly anti-VEGF therapy. Retina. 2014;34:417-424.
12. Elman MJ et al. Randomized trial of ranibizumab plus prompt or deferred laser. Ophthalmology. 2012.
13. Gulshan V et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy. JAMA. 2016;316:2402-2410.
